However, the potential associations between other polymorphisms – such as CDK4 rs2069502, CDK6 rs2285332, p16INK4a rs11515, p15INK4b rs3217986, RB rs3092904 – and prostate cancer risk have not yet been elucidated. Here, CDKN2B is linked to prostate carcinoma.